home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)

 
  February 03, 2021  
     
 
ComplianceOnline, online event
16 February 2021


DAY 01(7:00 AM - 1:00 PM PST)
  • The CMO Business Model
  • What is CMO Oversight?
  • CMO Oversight and COVID-19 Restrictions
  • Regulatory Requirements for CMO Oversight
  • FDA Expectations and Warning Letters
  • Structuring Your Organization for CMO Oversight
    • Manufacturing
    • Chemistry / Laboratory
    • Quality Assurance
    • Regulatory Affairs
    • Project Management
    • Group Exercise # 1- Structuring Your Organization
  • CMO Selection and Qualification
    • Overall Considerations
    • Selection Criteria / Process
    • Qualification Criteria / Process
    • Evaluating CMOs vs. Selection / Qualification Criteria
    • Case Study # 2- Example of Selection Scoring Matrix
  • CMO Audits (Remote Auditing Perspective)
    • Overall Considerations
    • Qualification vs. Routine Audits
    • CMO Questionnaires
      • Purpose of Questionnaires
      • Questionnaire Topics / Responses
    • Audit Planning
      • Audit Purpose / Scope
      • Audit Agenda
    • Audit Execution
      • Document Review / Interviews
      • Time Management
      • Audit Findings / CAPAs
    • Group Exercise # 3- Audit Agenda
  • The Quality Agreement
    • Regulatory Requirements
    • General Elements of the Quality Agreement
    • Negotiating the Quality Agreement
    • Executing the Quality Agreement
    • Case Study # 4- Quality Agreement: Key Pitfalls
DAY 02(7:00 AM - 1:00 PM PST)
  • Getting to Know Your CMO
    • Understanding CMO Operations
    • Operational/Communication Style
    • Case Study # 5- CMO Personality Types
  • Review of Key CMO Records
    • Batch Records
    • Change Controls
    • Deviation Investigations / CAPA
    • OOS Investigations
  • Hot Topic- Data Integrity
  • Ongoing CMO Oversight
    • Overall Considerations
    • Elements of Effective Ongoing CMO Oversight
 
 
Organized by: ComplianceOnline
Invited Speakers:

Andrew Campbell has 25 years of pharmaceutical quality assurance and quality systems experience in both industry and consulting roles. Mr. Campbell has worked in clinical supply and commercial manufacturing environments, and has experience with integrated manufacturing and contract manufacturing business models. He has extensive expertise in the areas of deviation - CAPA, change control, GMP auditing, GMP training, and regulatory inspection preparation and management.

Working with large and small companies, Mr. Campbell has successfully developed, remediated and implemented key quality systems. He is a skilled GMP auditor, and has audited multiple API, drug product, packaging, testing, and distribution facilities. He is an experienced GMP trainer, and has developed customized and interactive training presentations for many companies. He has also provided FDA inspection support for several clients, including readiness training, on-site assistance during inspections, and authoring written responses to inspectional observations. Prior to becoming a consultant in 2007, Mr. Campbell worked for Ligand Pharmaceuticals as director of quality systems.

 
Deadline for Abstracts: 16.2.2021
 
Registration: Register by phone or need assistance? Call +1-888-717-2436
 
 
 
 
E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.